Zyprexa appeal rejected by Supreme Court

The U.S. Supreme Court has refused to revive a bid to press a class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.

The justices on Monday turned away an appeal by pension funds, unions and insurers that claim they spent more for the drug than it was worth. The plaintiffs say Lilly violated a federal racketeering law by making fraudulent claims about Zyprexa’s safety and effectiveness, and promoting it for non-approved uses.

The group was seeking $6.8 billion on behalf of thousands of so-called third-party payors. A federal appeals court said the case wasn’t appropriate for class-action status and told a trial judge to consider whether the plaintiffs filing the suit could press their individual claims.

Indianapolis-based Lilly in 2009 pleaded guilty to promoting Zyprexa for unapproved uses and agreed to pay $1.4 billion in criminal and civil penalties. Zyprexa is its top-selling drug, with about $5 billion in annual sales.

Zyprexa will lose patent protection in October, costing Lilly most of those sales to cheaper generic copies.

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.